HK1253579A1 - 用於治療癌症的單克隆抗體 - Google Patents

用於治療癌症的單克隆抗體

Info

Publication number
HK1253579A1
HK1253579A1 HK18112784.5A HK18112784A HK1253579A1 HK 1253579 A1 HK1253579 A1 HK 1253579A1 HK 18112784 A HK18112784 A HK 18112784A HK 1253579 A1 HK1253579 A1 HK 1253579A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
cancer
treatment
monoclonal anti
monoclonal
Prior art date
Application number
HK18112784.5A
Other languages
English (en)
Inventor
Ugur Sahin
Özlem Türeci
Michael Koslowski
Rita Mitnacht-Kraus
Original Assignee
Astellas Pharma Inc
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc
Publication of HK1253579A1 publication Critical patent/HK1253579A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112784.5A 2008-09-16 2018-10-08 用於治療癌症的單克隆抗體 HK1253579A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
HK1253579A1 true HK1253579A1 (zh) 2019-06-21

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112784.5A HK1253579A1 (zh) 2008-09-16 2018-10-08 用於治療癌症的單克隆抗體

Country Status (26)

Country Link
US (1) US8946388B2 (zh)
EP (3) EP2166021A1 (zh)
JP (1) JP2012502938A (zh)
KR (1) KR101818741B1 (zh)
CN (3) CN105753988A (zh)
AU (1) AU2009294896B2 (zh)
BR (1) BRPI0918178B8 (zh)
CA (1) CA2732594C (zh)
CY (1) CY1119956T1 (zh)
DK (1) DK2342234T3 (zh)
ES (1) ES2659718T3 (zh)
HK (1) HK1253579A1 (zh)
HR (1) HRP20180262T1 (zh)
HU (1) HUE036477T2 (zh)
IL (2) IL211010A (zh)
LT (1) LT2342234T (zh)
MX (2) MX2011002856A (zh)
NO (1) NO2342234T3 (zh)
NZ (2) NZ591004A (zh)
PL (1) PL2342234T3 (zh)
PT (1) PT2342234T (zh)
RS (1) RS56937B1 (zh)
SI (1) SI2342234T1 (zh)
TR (1) TR201802090T4 (zh)
WO (1) WO2010031551A2 (zh)
ZA (1) ZA201100835B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP3656403B1 (en) 2007-08-17 2022-05-11 Purdue Research Foundation Preparation process of psma binding ligand-linker conjugates
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) * 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN107929730A (zh) * 2011-01-19 2018-04-20 坎塔吉亚有限责任公司 抗il1rap抗体及其治疗人类的用途
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
GEP20237496B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
RU2729396C2 (ru) * 2015-07-14 2020-08-06 МЕДИММЬЮН, ЭлЭлСи Композиции и способы лечения рака
WO2017041001A2 (en) * 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
CA3007033A1 (en) * 2015-12-01 2017-06-08 Genmab B.V. Anti-dr5 antibodies and methods of use thereof
US20200140565A1 (en) * 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
JP2020513819A (ja) * 2017-03-15 2020-05-21 スージョウ ギャラクシー バイオファーマ カンパニー リミテッド Ｃｔｌａ４抗体、医薬組成物およびその使用
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
JP4624977B2 (ja) 2003-01-17 2011-02-02 ザ チャイニーズ ユニバーシティ オブ ホンコン 妊娠障害診断マーカーとしての血中ｍＲＮＡ
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物

Also Published As

Publication number Publication date
IL242204A0 (en) 2015-11-30
SI2342234T1 (en) 2018-04-30
CY1119956T1 (el) 2018-12-12
HRP20180262T1 (hr) 2018-03-23
BRPI0918178A2 (pt) 2015-12-01
EP2342234B1 (en) 2017-11-15
NZ596490A (en) 2013-05-31
MX2011002856A (es) 2011-06-28
DK2342234T3 (en) 2018-02-26
CN102164963A (zh) 2011-08-24
WO2010031551A3 (en) 2010-09-16
CN105753988A (zh) 2016-07-13
HUE036477T2 (hu) 2018-07-30
KR101818741B1 (ko) 2018-01-15
CN104628858B (zh) 2018-11-16
IL242204B (en) 2020-09-30
RS56937B1 (sr) 2018-05-31
EP2166021A1 (en) 2010-03-24
US8946388B2 (en) 2015-02-03
ES2659718T3 (es) 2018-03-19
MX357010B (es) 2018-06-22
CN102164963B (zh) 2015-07-29
BRPI0918178B8 (pt) 2021-05-25
BRPI0918178B1 (pt) 2021-04-06
ZA201100835B (en) 2014-04-30
NZ591004A (en) 2012-03-30
NO2342234T3 (zh) 2018-04-14
EP2342234A2 (en) 2011-07-13
WO2010031551A2 (en) 2010-03-25
TR201802090T4 (tr) 2018-03-21
AU2009294896A1 (en) 2010-03-25
EP3312198A1 (en) 2018-04-25
CN104628858A (zh) 2015-05-20
BRPI0918178A8 (pt) 2020-05-19
LT2342234T (lt) 2018-03-12
KR20110055699A (ko) 2011-05-25
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
IL211010A0 (en) 2011-04-28
PT2342234T (pt) 2018-02-21
CA2732594A1 (en) 2010-03-25
IL211010A (en) 2015-11-30
US20110223182A1 (en) 2011-09-15
JP2012502938A (ja) 2012-02-02
PL2342234T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
HK1253579A1 (zh) 用於治療癌症的單克隆抗體
IL238668A0 (en) Monoclonal antibodies against cld18 for cancer treatment
HK1209653A1 (zh) 用於腫瘤治療的單克隆抗體
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
PT2550296T (pt) Anticorpos monoclonais para tratamento do cancro
EP2385114A4 (en) CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
EP2331130A4 (en) IGE ANTIBODIES FOR THE TREATMENT OF CANCER
EP2281575A4 (en) ANTIBODIES FOR THE TREATMENT OF CANCER
IL207478A0 (en) Monoclonal antibodies for tumor treatment
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy